A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Eleos, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02243124
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
Phase 2
Withdrawn
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Eleos, Inc.
- Registration Number
- NCT00967512
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
Phase 2
Completed
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2003-12-23
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Eleos, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT00074737
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸University of Miami Health Center, Miami, Florida, United States
🇺🇸North Shore University Hospital, Lake Success, New York, United States
© Copyright 2025. All Rights Reserved by MedPath